Knockout screening with Sanger arrayed genome-wide CRISPR libraries
We present the first genome wide, arrayed guide RNA screening libraries for CRISPR-Cas9. These libraries have been designed to cover 17166 human and 20430 mouse genes. To test the efficiency, we selected gRNAs targeting genes from the GPI anchor protein pathway. We observed that over 95% of these gRNAs successfully induced DNA cleavage and consequently gene loss of function. These libraries offer the prospect for performing high-throughput screens for genes of considerable scientific and therapeutic value in mouse and human cells.
Emmanouil Metzakopian, PhD, WTSI Career Development Fellow PDUK Senior Research Fellow, Wellcome Trust Sanger Institute
Dr. Metzakopian is a research fellow at Wellcome Trust Sanger Institute, where he focuses on identifying genes which confer resistance to chemotherapy drugs in embryonic stem cells and to oxidative stress agents in dopamine neurons.
Shawn Shafer, PhD, Advanced Genomics Market Segment Manager, MilliporeSigma
Dr. Shafer leads a team responsible for product development of MilliporeSigma’s RNAi and genome editing portfolios. He orchestrated the creation of Sigma-Aldrich’s CRISPR collection of reagents.
Supported by Merck KGaA
Merck KGaA, Darmstadt, Germany is a leading company for innovative and top-quality high-tech products in healthcare, life science and performance materials. The company has six businesses – Biopharmaceuticals, Consumer Health, Allergopharma, Biosimilars, Life Science and Performance Materials – and generated sales of €12.85 billion in 2015. Around 50,000 employees work in 66 countries to improve the quality of life for patients, to foster the success of customers and to help meet global challenges.
Find out more: www.merckmillipore.com